U.S. Markets close in 19 mins
  • S&P 500

    4,182.79
    -39.07 (-0.93%)
     
  • Dow 30

    33,408.92
    -414.53 (-1.23%)
     
  • Nasdaq

    14,064.65
    -96.70 (-0.68%)
     
  • Russell 2000

    2,237.73
    -49.73 (-2.17%)
     
  • Crude Oil

    71.75
    +0.71 (+1.00%)
     
  • Gold

    1,771.60
    -3.20 (-0.18%)
     
  • Silver

    25.94
    +0.08 (+0.32%)
     
  • EUR/USD

    1.1881
    -0.0030 (-0.2495%)
     
  • 10-Yr Bond

    1.4500
    -0.0610 (-4.04%)
     
  • Vix

    19.43
    +1.68 (+9.46%)
     
  • GBP/USD

    1.3811
    -0.0113 (-0.8093%)
     
  • USD/JPY

    110.1250
    -0.1060 (-0.0962%)
     
  • BTC-USD

    35,479.82
    -2,444.14 (-6.44%)
     
  • CMC Crypto 200

    876.54
    -63.41 (-6.75%)
     
  • FTSE 100

    7,017.47
    -135.96 (-1.90%)
     
  • Nikkei 225

    28,964.08
    -54.25 (-0.19%)
     

Wave Life Sciences to Present at RBC Capital Markets Global Healthcare Virtual Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer is scheduled to give a presentation at the RBC Capital Markets Global Healthcare Virtual Conference on Wednesday, May 19, 2021 at 4:15 p.m. ET.

A live webcast of the presentation will be available on the investor relations page of the Wave Life Sciences corporate website at http://ir.wavelifesciences.com. A replay of the presentation will be archived and available at that site for 90 days following the event.

About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit www.wavelifesciences.com and follow Wave on Twitter @WaveLifeSci.

Investor Contact:
Kate Rausch
617-949-4827
krausch@wavelifesci.com

Media Contact:
Alicia Suter
617-949-4817
asuter@wavelifesci.com